Flow cytometric analysis of Human CD257 expression on U-937 cells. Cells from the Daudi (Human Burkitt's lymphoma lymphoblast, Left) / U-937 (Human histiocytic lymphoma monocyte, Right) labelling SDT APC Mouse Anti-Human CD257 Antibody at 1.25 μl/test / (Red line histogram) compared with a APC Mouse IgG2a, κ (Black line histogram) isotype control. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software. Negative control: Daudi
APC Mouse Anti-Human CD257 Antibody (S-3021)
APC Mouse Anti-Human CD257 Antibody (S-3021)
Price:
Regular price
$242.00 SGD
Regular price
Sale price
$242.00 SGD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD257 |
| Synonyms | Tumor necrosis factor ligand superfamily member 13B; B lymphocyte stimulator (BLyS); B-cell-activating factor; BAFF; Dendritic cell-derived TNF-like molecule; TNF- and APOL-related leukocyte expressed ligand 1 (TALL-1); BLYS; TALL1; TNFSF20; ZTNF4; TNFSF13B |
| Location | Cell membrane |
| Accession | Q9Y275 |
| Clone Number | S-3021 |
| Antibody Type | Mouse mAb |
| Isotype | IgG2a,k |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | U-937 |
| Purification | Protein A |
| Concentration | 0.2 mg/ml |
| Conjugation | APC |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1.25μl per million cells in 100μl volume | Hu |
Background
CD257 is a 285-aa type-II transmembrane glycoprotein of the TNF ligand superfamily produced by monocytes, dendritic cells, macrophages and activated T cells that can be cleaved to a soluble homotrimeric cytokine which, via engagement of three receptors—BAFF-R, TACI and BCMA—delivers survival and maturation signals to B cells, orchestrates T-cell co-stimulation, and drives class-switching and antibody production through NF-κB and PI3K/AKT pathways, while excess CD257 triggers B-cell hyperplasia and autoantibody formation, linking its overexpression to systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis and multiple myeloma, and making CD257 antagonism (e.g., belimumab) a validated therapeutic strategy.
Picture
Picture
FC
